FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Down 47.8% in July

Posted by Stanley Muller on Jul 29th, 2026

FibroBiologics Inc. (NASDAQ:FBLG – Get Free Report) saw a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 70,837 shares, a drop of 47.8% from the June 30th total of 135,794 shares. Based on an average daily trading volume, of 59,556 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.3% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

FBLG has been the topic of several recent research reports. Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday. HC Wainwright reissued a “buy” rating and set a $8.00 target price (up from $4.00) on shares of FibroBiologics in a report on Thursday, April 16th. Maxim Group downgraded shares of FibroBiologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Finally, Wall Street Zen raised shares of FibroBiologics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, FibroBiologics currently has an average rating of “Hold” and an average price target of $74.00.

Get Our Latest Analysis on FBLG

Institutional Trading of FibroBiologics

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in shares of FibroBiologics in the fourth quarter valued at approximately $34,000. Renaissance Technologies LLC lifted its position in shares of FibroBiologics by 287.3% during the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after buying an additional 171,800 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of FibroBiologics by 20.7% during the 4th quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock valued at $78,000 after buying an additional 59,813 shares in the last quarter. AMG National Trust Bank purchased a new position in shares of FibroBiologics during the 4th quarter valued at approximately $31,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in FibroBiologics in the 3rd quarter valued at $191,000.

FibroBiologics Trading Up 0.1%

Shares of FibroBiologics stock traded up $0.00 during trading hours on Wednesday, reaching $0.65. The stock had a trading volume of 56,933 shares, compared to its average volume of 252,359. The stock’s 50 day moving average is $0.89 and its 200 day moving average is $3.11. FibroBiologics has a twelve month low of $0.62 and a twelve month high of $13.16. The firm has a market capitalization of $3.96 million, a PE ratio of -0.09 and a beta of 1.14.

FibroBiologics (NASDAQ:FBLG – Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($1.33) EPS for the quarter, meeting analysts’ consensus estimates of ($1.33). As a group, sell-side analysts predict that FibroBiologics will post -4.01 earnings per share for the current year.

About FibroBiologics

(Get Free Report)

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.